[go: up one dir, main page]

ES2103468T3 - Tratamiento de la inflamacion intestinal. - Google Patents

Tratamiento de la inflamacion intestinal.

Info

Publication number
ES2103468T3
ES2103468T3 ES93904830T ES93904830T ES2103468T3 ES 2103468 T3 ES2103468 T3 ES 2103468T3 ES 93904830 T ES93904830 T ES 93904830T ES 93904830 T ES93904830 T ES 93904830T ES 2103468 T3 ES2103468 T3 ES 2103468T3
Authority
ES
Spain
Prior art keywords
treatment
intestinal inflammation
tissus
ibd
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93904830T
Other languages
English (en)
Inventor
Roy R Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2103468(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2103468T3 publication Critical patent/ES2103468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE (IBD) (INFLAMMATORY BOWEL DISEASE O). EL METODO COMPRENDE LA ADMINISTRACION DE UN ANTICUERPO, POLIPEPTIDO U OTRA MOLECULA COMPRENDIENDO VLA-4, UNA MOLECULA SUPERFICIAL EXPRESADA EN LA MAYOR CLASE DE TIPOS DE GLOBULOS SANGUINEOS BLANCOS E IMPLICADA EN LA ADHERENCIA DE LEUCOCITOS AL ENDOTELIO Y OTROS TEJIDOS EN EL TUBO DIGESTIVO.
ES93904830T 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal. Expired - Lifetime ES2103468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12

Publications (1)

Publication Number Publication Date
ES2103468T3 true ES2103468T3 (es) 1997-09-16

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93904830T Expired - Lifetime ES2103468T3 (es) 1992-02-12 1993-02-02 Tratamiento de la inflamacion intestinal.

Country Status (11)

Country Link
EP (1) EP0625912B1 (es)
JP (3) JPH07506566A (es)
AT (1) ATE151642T1 (es)
AU (1) AU674302B2 (es)
CA (1) CA2129637C (es)
DE (1) DE69309906T2 (es)
DK (1) DK0625912T3 (es)
ES (1) ES2103468T3 (es)
GR (1) GR3024041T3 (es)
HK (1) HK1007683A1 (es)
WO (1) WO1993015764A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5843438A (en) 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DK1113810T3 (da) 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
MX340683B (es) 2010-04-16 2016-07-21 Biogen Ma Inc Anticuerpos anti-vla-4.
PH12018502221B1 (en) 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
HUT69725A (en) * 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection

Also Published As

Publication number Publication date
GR3024041T3 (en) 1997-10-31
CA2129637C (en) 1999-05-04
JP2007045843A (ja) 2007-02-22
JP4108572B2 (ja) 2008-06-25
DK0625912T3 (da) 1997-10-27
DE69309906T2 (de) 1997-11-06
JPH07506566A (ja) 1995-07-20
AU674302B2 (en) 1996-12-19
EP0625912B1 (en) 1997-04-16
JP2004002472A (ja) 2004-01-08
WO1993015764A1 (en) 1993-08-19
EP0625912A1 (en) 1994-11-30
DE69309906D1 (de) 1997-05-22
AU3605993A (en) 1993-09-03
CA2129637A1 (en) 1993-08-19
HK1007683A1 (en) 1999-04-23
ATE151642T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
ES2103468T3 (es) Tratamiento de la inflamacion intestinal.
CA2235272A1 (en) System for collection of blood without damage
DE69309044D1 (de) Behandlung von asthma
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
FR2633940B3 (fr) Scleroglucane traite au glyoxal et son procede d'obtention
DE68927459D1 (de) Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
CA2080462A1 (en) Therapeutic uses of actin-binding compounds
PT81991A (fr) Procede pour l'obtention de derives analogues de la pepstatine inhibidors de la renine et de proteases acides
ES2086521T3 (es) Proteina hibrida laci-factor x.
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
DE69025294D1 (de) Pump- und Behandlungssystem für Blut
ES2043900T3 (es) Conjugados de haptenos y proteinas y su utilizacion.
WO1998051780A3 (en) Method for increasing yields or recombinant proteins
RU94020406A (ru) Способ выявления поражений эпителия желудка и применение дисахаридов для этой цели
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
RU96109171A (ru) Способ идентификации тела погибшего
EP0749981A4 (en) MONOCLONAL ANTIBODY
RU93004826A (ru) Способ мездрения кож и шкур
DE69023500D1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
UA15941A (uk) Спосіб діагhостики початкових стадій гіпертоhічhої хвороби
RU95106901A (ru) Способ моделирования антиперистальтики кишечника в эксперименте
荒木雅弘 Klaus-Jurgen Engelberg:" Lexical Functional Grammar in Speech Recognition", Proc. of the 12th International Conference on Computational Linguistics, pp. 172-176 (1988).
RU95105698A (ru) Способ получения сыворотки против pasteurella multocida

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625912

Country of ref document: ES